From review to approval: medical device labeling workflow

Medical device labeling is held to some of the strictest documentation standards in regulated industries. A single inconsistency in an IFU, a missed update in a DFU, or a barcode error on packaging can delay market access — or trigger a costly recall.

Unlike pharmaceutical labeling, medical device documentation adds unique complexity: Instructions for Use (IFUs) and Directions for Use (DFUs) run to dozens of pages with multi-page tables, technical diagrams, and safety symbols. Translated versions must preserve formatting precision as well as textual accuracy. And with MDR and IVDR tightening requirements across Europe, the margin for error has never been smaller.

This guide walks through the complete medical device labeling and documentation workflow — stage by stage — identifying where errors occur and how TVT helps teams eliminate them before they reach market.

The unique documentation challenge in medical devices

Medical device manufacturers face labeling complexity that goes well beyond packaging text. IFUs for surgical instruments, diagnostic equipment, or implantable devices may contain hundreds of pages of procedural instructions, complex tables, safety warnings, and embedded technical illustrations — all of which must be flawlessly reproduced across multiple language versions and format types.

Regulatory frameworks such as EU MDR (2017/745), IVDR (2017/746), and FDA 21 CFR Part 801 impose strict requirements on the accuracy and traceability of this documentation. A formatting change that alters the reading order of a safety instruction, or a table that shifts incorrectly in translation, is not just an aesthetic problem — it is a compliance failure.

Under EU MDR, manufacturers are required to maintain a technical file with up-to-date labeling documentation. Any post-market labeling change must be traceable and documented — making an auditable verification workflow not just best practice, but a regulatory requirement.

Step 1 — Clinical trials and submission phase

The documentation lifecycle begins during the clinical and regulatory submission phase. At this stage, manufacturers prepare labeling content — device labels, IFUs, DFUs, and clinical trial labeling — for submission to health authorities including the FDA, EMA, notified bodies, and national competent authorities.

Complex submission dossiers contain multiple interconnected documents that must remain internally consistent throughout the review process. Regulatory queries and revision cycles are common, and each revision carries the risk of introducing discrepancies between documents that were previously aligned.

Step 2 — Documentation and promotional materials development phase

Once a device moves toward approval or market launch, teams develop both detailed technical documentation and promotional content in parallel. IFUs and DFUs at this stage can be extensive — multi-page documents with complex table structures, procedural step sequences, contraindication lists, and technical diagrams — all of which must be verified for accuracy before they are handed off for translation or artwork.

Simultaneously, advertising and promotional materials must align their claims with the cleared or approved device indications. Any deviation between promotional claims and the device’s cleared labeling creates a regulatory exposure that can be difficult to detect through manual review alone.

This dual burden — verifying both the precision of technical documentation and the accuracy of promotional claims — makes this the most content-intensive phase of the medical device labeling workflow.

Step 3 — Artwork and e-labeling development phase

The artwork phase translates approved documentation into physical and digital labeling — device packaging, carton text, translated IFU booklets, eIFU files, and QR-linked digital labeling. For medical devices, this phase carries particular risks: IFUs are often translated into 30 or more languages, technical content must survive the translation and typesetting process intact, and barcode and QR code links must resolve correctly to the right eIFU version.

Accessibility is also a regulatory concern at this stage. The EU Accessibility Act and Section 508 in the US require that digital labeling be structured with a correct and verifiable reading order — something that can easily be disrupted during artwork layout without automated checking.

Step 4 — Pre-press, publishing, and printing phase

The final stage hands approved artwork to packaging manufacturers and print suppliers for production. At this point, even small deviations — a pictogram rendered at the wrong size, a color scheme that deviates from brand or regulatory requirements, a logo that shifts position — can create compliance or brand integrity issues that require expensive reprinting or trigger a non-conformance.

For medical device manufacturers operating under quality management systems aligned to ISO 13485, the ability to document and demonstrate that supplier outputs were verified against approved artwork is not optional — it is part of the quality record.

Where medical device labeling workflows break down

The failure modes in medical device labeling are structurally similar to pharma — but the documentation volume and regulatory stakes are often higher. IFU accuracy directly affects patient safety, and a labeling non-conformance can halt a product launch across entire regulatory regions.

• IFU complexity outpaces manual review — Multi-page tables, technical diagrams, and procedural sequences cannot be reliably reviewed by eye across dozens of language versions. Small formatting changes in table structure or step numbering can change clinical meaning.
• Disconnected documentation and artwork systems — Regulatory documentation is approved in one system; artwork is managed in another. Updates to approved IFU content rarely propagate automatically into the artwork workflow.
• Translation volume creates compounding risk — A single device with 30+ language versions multiplies every documentation error across every market. An error caught in one language version may exist undetected in 15 others.
• Regulatory audit exposure without a unified trail — MDR and ISO 13485 require demonstrable evidence that labeling has been verified. Without automated, documented verification at each stage, audit preparation becomes a significant resource burden.

How TVT fits into your medical device labeling ecosystem

TVT operates as a verification layer across the tools and systems medical device manufacturers already use — adding automated checking and QMS-aligned audit documentation at each critical handoff without replacing existing workflows.

• Works alongside

Veeva Vault, Esko (built-in), artwork management systems, RIM platforms, QMS systems, and PLM and LIMS environments

• Regulatory alignment

Supports compliance with EU MDR, IVDR, FDA 21 CFR Part 11, ISO 13485, Section 508, and the EU Accessibility Act

• Supported formats

PDF, Word, Excel, HTML, XML, Adobe Illustrator, PPT — and cross-format comparison between any of these

• Key differentiators

Many-to-one and one-to-many modes, complex table comparison, multilingual support including non-Latin scripts, and XML audit exports for supplier tracking